Important Note: Redirection of Services to ChiCTR
We would like to inform you that the Clinical Trial Registry page will discontinue the function of updating trial information directly on this platform. However, you will still be able to view the existing registration details. For any updates to trial information, you can use the China Clinical Trial Registry (ChiCTR) directly at https://www.chictr.org.cn. This change will be fully implemented by 2024-Aug-05. Thank you for your attention.
CUHK_CCT00251
2010-07-06
Retrospective
Nil
CUHK
CUHK
Nil
Cheuk Man Yu
Rm. 104041, 8/F
2632 3197
cmyu@cuhk.edu.hk / poonsps@yahoo.com.hk
Nil
Cheuk Man Yu / Sheung Poon
Rm. 104041, 8/F
2632 3197
cmyu@cuhk.edu.hk / poonsps@yahoo.com.hk
Nil
MAtilda Hospital and Chinese University Shock Wave therapy for Ischemic Myocardium (MACUSWIM)
MAtilda Hospital and Chinese University Shock Wave therapy for Ischemic Myocardium (MACUSWIM)
MACUSWIM
Hong Kong
Yes
2008-04-07
Ischemic Cardiomyopathy
Procedure
Shock Wave therapy the patients with Ischemic Myocardium
2 years
60 stable chronic angina patients with either coronary artery disease that is not amenable for revascularization or triple vessel coronary artery disease awaiting coronary artery bypass grafting will undergo baseline exercise testing, echocardiography, magnetic resonance imaging, and questionnaire assessment of symptoms. After randomization, they will then undergo ultrasound shock wave therapy for 20 minutes, three times a week on either the first, fifth, and ninth week of the study or the 18th, 23rd, and 27th week of the study. Three blood tests will be taken during the first 12 hours after shock wave to monitor cardiac muscle enzyme and growth factor enzymes. MRI heart, Exercise testing, and echocardiography would be performed at 6 months and coronary artery bypass grafting would be performed at 6 months. Follow up questionnaire and clinical assessment would be performed at 6 and 12 months FU. Patients randomized to non treatment arm will undergo MRI, exercise tests, questionnaires and echocardiography but will not attend for shock wave therapy.
1. Patient is male or female between 18 and 85 years of age on day of signing informed consent.
2. Contraception for female patients who are of reproductive potential: a female
patient who is of reproductive potential agrees to remain abstinent or use (or have
their partner use) 2 acceptable methods of birth control for the duration of the study.
An acceptable method of birth control is defined as: intrauterine device (IUD),
diaphragm with spermicide, contraceptive sponge, condom, vasectomy.
Note: Female patients who have reached menopause, undergone hysterectomy,
bilateral oophorectomy, or bilateral tubal ligation are eligible without the use of
contraceptives.
3. Patients with coronary angiography demonstrating coronary anatomy not amenable to revascularization or suitable for routine elective coronary artery bypass grafting with impaired LVEF < 40% and with substantial viable reversible myocardial ischemia in at least one vascular territory on MRI
1. Pregnancy or lactation.
2. Any other condition which in the opinion of the investigator may either put the patient at risk or influence the result of the study (eg. severe respiratory disease, severe valvular disease, cardiogenic shock, active myocarditis / endocarditis, hemodynamic instability, malignancy, non-compliance, risk of lost to follow up, conditions leading to life expectancy of less than 24 months).
3. Participation in other clinical trial within 6 months of enrollment.
4. Recent myocardial infarction within 6 months.
5. Unable to consent to or perform components of the study
18 years of age
85 year of age
Both Male and Female
Interventional
Randomized
Active
Open label
Parallel
2008-02-04
60patients
Recruiting
Primary end point:
- Improved Exercise duration on standard Bruce Protocol Exercise test
Secondary endpoints:
- Improved angina frequency.
-Improved CCS angina grade.
-Improved 6 minute walk.
-Improved SF-36.
2012-12-28
Yes
Nil
|
|
|
|
|
---|---|---|---|---|
No documents yet. |